Global Graft Versus Host Disease Gvhd Treatment Market
市场规模（十亿美元）
CAGR :
% 
USD
4.07 Billion
USD
5.81 Billion
2024
2032
 Forecast Period |
2025 –2032 |
 Market Size (Base Year) |
USD 4.07 Billion |
 Market Size (Forecast Year) |
USD 5.81 Billion |
 CAGR |
% |
| Major Markets Players |
|
全球移植物抗宿主疾病 (GVHD) 治療市場，按治療（藥物和療法）、類型（慢性 GVHD、急性 GVHD 和預防性）、性別（女性和男性）、年齡（成人和兒童）、給藥方式（口服、靜脈注射、外用和其他）、最終用戶（醫院、移植中心、研究所和專科中心）、分銷渠道（直接預測和其他行業）
全球移植物抗宿主疾病（GVHD）治療市場規模
- 2024 年全球移植物抗宿主疾病 (GVHD) 治療市場價值為40.7 億美元，預計到 2032 年將達到58.1 億美元
- 在 2025 年至 2032 年的預測期內，市場可能會以4.7% 的複合年增長率成長，主要原因是肥胖症盛行率的上升。
- 這種成長受到抗移植物抗宿主疾病 (GVHD) 藥物創新、減重和代謝手術成長等因素的推動。此外，數位健康解決方案也融入了移植物抗宿主疾病（GVHD）治療中。
全球移植物抗宿主疾病（GVHD）治療市場分析
- 幹細胞移植數量的增加和治療方法的進步是推動市場成長的一些主要因素
- 此外，新療法的開發也進一步推動了市場的成長。然而，影響市場成長的主要限制因素是治療成本高昂
- 另一方面，醫療保健提供者、患者和護理人員對 GVHD 的認識和教育不斷提高，有望為市場成長創造機會。然而，感染和其他併發症的風險預計將對市場成長構成挑戰
- 北美仍然是全球移植物抗宿主疾病 (GVHD) 治療市場的主導地區，得益於完善的醫療基礎設施、高盛行率以及對體重管理解決方案的持續研究
- 隨著對移植物抗宿主疾病 (GVHD) 管理和預防性醫療保健的日益重視，全球市場正在對新療法、醫療技術和以患者為中心的解決方案進行大量投資，推動整個行業的擴張
報告範圍和移植物抗宿主疾病 (GVHD) 治療市場細分
|
屬性 |
全球移植物抗宿主疾病 (GVHD) 治療市場關鍵市場洞察 |
|
涵蓋的領域 |
|
|
覆蓋國家 |
北美。
歐洲
亞太地區
南美洲
中東和非洲
|
|
主要市場參與者 |
|
|
市場機會 |
|
|
加值資料資訊集 |
除了對市場價值、成長率、細分、地理覆蓋範圍和主要參與者等市場情景的洞察之外，Data Bridge Market Research 策劃的市場報告還包括進出口分析、生產能力概覽、生產消費分析、價格趨勢分析、氣候變遷情景、供應鏈分析、價值鏈分析、原材料/消耗品概覽、供應商選擇標準、PESTLE 分析、波特分析和監管框架。 |
全球移植物抗宿主疾病 (GVHD) 治療市場趨勢。
“造血幹細胞移植（HSCT）的發生率不斷增加”
- 這一趨勢主要是由於白血病、淋巴瘤和骨髓瘤等血癌的發生率不斷上升所致，這些疾病通常需要採用造血幹細胞移植作為治療選擇。此外，其他血液疾病，如再生障礙性貧血和某些遺傳性疾病，也需要透過造血幹細胞移植進行疾病管理
- 隨著接受 HSCT 的患者數量不斷增加，對有效 GVHD 治療的需求也不斷增加。 GVHD 是 HSCT 的常見併發症，當移植的供體細胞攻擊接受者的組織時就會發生，從而導致潛在的嚴重和危及生命的症狀。因此，造血幹細胞移植 (HSCT) 發生率的不斷上升直接意味著需要更高的 GVHD 治療來管理和減輕這種併發症的影響
例如，
- 2023 年 10 月，根據 Frontiers Media SA 發表的一篇文章，全球移植數量正在穩步增長，歐洲血液和骨髓移植協會 (EBMT) 報告稱，2019 年進行了近 20,000 例異基因造血幹細胞移植 (allo-HCT)，而國際血液和骨髓移植研究中心 (CIBMTR) 進行了同期移植研究中心的數據
全球移植物抗宿主疾病 (GVHD) 治療市場動態
司機
“加強意識宣傳和病患教育”
- 宣傳活動和病患教育對於移植物抗宿主疾病 (GVHD) 的早期發現和治療至關重要。這些措施專門針對醫療保健專業人員、患者和護理人員，突出了主要的 GVHD 症狀，以便及時識別和乾預
- 受過教育的患者和照護者更有可能儘早尋求醫療建議，防止疾病發展到嚴重階段。此外，熟悉 GVHD 症狀和管理的醫療保健提供者可以提供更有效的護理，改善患者的治療效果。這些有針對性的努力對於提高受 GVHD 影響的人的整體生活品質至關重要。
例如，
- 2023 年 8 月，根據 Fierce Pharma 發表的一篇文章，足球傳奇人物米婭哈姆 (Mia Hamm) 與 Incyte 合作，提高人們對移植物抗宿主疾病 (GVHD) 的認識。哈姆分享了她的個人經歷：1997 年，她的哥哥加勒特因骨髓移植 (BMT) 併發症去世。骨髓移植旨在治療罕見的骨髓疾病，但存在很大的移植物抗宿主疾病 (GVHD) 風險，即移植物的免疫細胞會攻擊接受者的細胞。這種情況在移植後可能難以控制，在某些情況下甚至可能致命
- 2023 年 2 月，美通社報導，在美國，新成立的由領先的移植組織組成的 GVHD 聯盟旨在增強受移植物抗宿主疾病 (GVHD) 影響的個人獲得資源和支持的機會。該聯盟已將 2 月 17 日定為 GVHD 日，以提高人們對 GVHD 社群的認識和支持。成員組織包括美國移植和細胞治療協會 (ASTCT)、Be The Match（由國家骨髓捐贈計劃運營）、血液和骨髓移植資訊網路 (BMT InfoNet)、梅雷迪思 A. 考登基金會和國家骨髓移植連結 (nbmtLINK)。該聯盟旨在將患者與社會工作者和患者導航員等支持團體和資源聯繫起來，幫助他們倡導治療並解決他們的擔憂
機會
“透過策略性舉措和合作夥伴關係拓展市場”
- 對於在 GVHD（移植物抗宿主疾病）治療市場運營的公司來說，透過策略合作進行市場擴張可能是一種非常有效的方法
- 隨著對 GVHD 創新治療和綜合護理解決方案的需求不斷增長，公司可以利用策略合作夥伴關係和協作來擴大其市場份額，並提供多樣化的產品組合，以滿足不斷變化的患者需求。透過與研究機構、學術中心和生物技術公司合作，GVHD 市場參與者可以獲得尖端技術、新型治療方法和科學專業知識，以推進其產品開發工作
- 這些合作使公司能夠加速有前景的 GVHD 療法的發現和開發，包括個人化細胞療法、標靶生物製劑和支持性護理幹預
- 此外，與關鍵意見領袖和患者權益團體建立策略聯盟，有助於促進市場准入，並透過培養信任、信譽和患者參與度來提高新療法的採用率
- 2021 年 3 月，根據百時美施貴寶發表的一篇文章，百時美施貴寶 (BMS) 和 Bluebird Bio 已建立戰略合作夥伴關係，共同開發 Abecma，這是一流的 BCMA 指導的個性化免疫細胞療法，以一次性輸注的方式為三類暴露的多發性骨髓瘤患者提供。它是一種 B 細胞成熟抗原 (BCMA) 抗原受體 T 細胞療法，專為治療移植物抗宿主疾病 (GVHD) 而設計。此次合作充分利用了 Bluebird Bio 在細胞治療領域的深厚專業知識和 BMS 廣泛的全球商業化能力。目標是透過推動創新治療方案來解決未來 GVHD 患者未滿足的醫療需求，為 GVHD 領域的突破性療法鋪平道路
- 2022 年 11 月，Labiotech UG 的一項研究表明，諾華公司與 Gamida Cell 合作開發和商業化針對高風險血液系統惡性腫瘤患者的研究性先進細胞療法 omidubicel。 Omidubicel 旨在透過擴大可供移植的幹細胞的可用性來改善骨髓移植的結果。此次合作體現了一項策略性舉措，旨在解決血液腫瘤學領域尚未滿足的需求，並有望應用於移植物抗宿主疾病（GVHD）治療
- 此外，透過策略性措施進行市場擴張使 GVHD 市場參與者能夠實現產品組合多樣化，並佔據 GVHD 市場的更大份額
克制/挑戰
“GVHD治療的嚴格規定”
- 與舊的相比，GVHD 的監管指南更為嚴格。製造商必須在獲得批准之前對產品做出具體的改變，這預計會造成延誤。
- 嚴格的監管對未來的 GVHD 市場提出了重大挑戰。隨著該領域不斷進步，新療法和治療方式不斷發展，監管機構對安全性、有效性和品質控制實施了嚴格的標準
- 滿足這些監管要求需要在臨床前和臨床開發方面進行大量投資，以及提交大量文件和數據以供監管部門批准。此外，GVHD 的複雜性、異質性表現以及缺乏標準化的診斷標準進一步使監管評估和審批流程複雜化
例如，
- 2023年4月，根據FDA發表的文章，幹細胞研究在美國已經合法化，但是，其資金方面有一定的限制。生物製品評估與研究中心 (CBER) 負責監管細胞治療產品、人類基因治療產品以及與細胞和基因治療相關的某些設備。雖然 FDA 在確保治療的安全性和有效性方面發揮著至關重要的作用，但監管過程可能非常嚴格且耗時。此外，FDA 不斷變化的監管環境和嚴格的上市後監管要求需要持續的合規努力，並可能影響新療法進入市場的速度
- 嚴格的監管是未來 GVHD 市場面臨的重大挑戰，影響產品開發時間表、成本和市場准入
全球移植物抗宿主疾病 (GVHD) 治療市場範圍
市場根據類型、產品類型、吸收部位、年齡層、來源、交付方式、性別和分銷管道進行細分。
|
分割 |
細分 |
|
治療 |
|
|
類型 |
|
|
性別 |
|
|
年齡 |
|
|
給藥方法 |
|
|
最終用戶 |
|
|
分銷管道 |
|
全球移植物抗宿主疾病（GVHD）治療市場區域分析
“北美是1型和2型糖尿病胰島素市場的主導地區”
- 北美引領全球移植物抗宿主疾病 (GVHD) 治療市場，這得益於肥胖症的高盛行率、先進的醫療保健基礎設施以及創新體重管理解決方案的廣泛採用。
- 由於對 GLP-1 受體激動劑、減肥手術和數位體重管理平台等藥物治療的需求不斷增長，美國佔據了相當大的市場份額。
- 此外，人們對肥胖相關健康風險的認識不斷提高，以及人工智慧減肥計劃、遠距醫療諮詢和非侵入性治療解決方案的日益普及，繼續推動該地區的市場擴張。
“北美預計將實現最高成長率”
- 預計北美地區將在全球移植物抗宿主疾病 (GVHD) 治療市場中實現最高成長率，這得益於移植物抗宿主疾病 (GVHD) 盛行率的上升、醫療保健投資的增加以及人們對體重管理解決方案的認識的不斷提高。
- 由於生活方式的轉變、城市化進程的加快以及肥胖相關健康併發症的增多，美國、加拿大和墨西哥等國家正在成為主要市場。
- 美國醫療保健基礎設施不斷擴大，對醫療減重治療的需求不斷增長，仍然是移植物抗宿主疾病 (GVHD) 管理的重要市場。該國正在見證藥物治療、減肥手術和數位化體重管理計劃的採用率不斷提高。
全球移植物抗宿主疾病 (GVHD) 治療市場份額
市場競爭格局提供了競爭對手的詳細資訊。詳細資訊包括公司概況、公司財務狀況、收入、市場潛力、研發投資、新市場計劃、全球影響力、生產基地和設施、生產能力、公司優勢和劣勢、產品發布、產品寬度和廣度、應用優勢。以上提供的數據點僅與公司對市場的關注有關。
市場中主要的市場領導者有：
- 百時美施貴寶公司（美國）
- 艾伯維公司（美國）
- 諾華公司（瑞士）
- 詹森全球服務有限公司（美國）
- Mallinckrodt（美國）
- Incyte（美國）
- 賽諾菲（法國）
- Alkem Laboratories Ltd.（印度）
全球移植物抗宿主疾病（GVHD）治療市場的最新發展
- 2025年2月，美國FDA核准了首個單環內醯胺類/β-內醯胺酶抑制劑組合EMBLAVEO（氨曲南和阿維巴坦），用於治療治療選擇有限的成人複雜性腹腔內感染（cIAI）。它針對的是革蘭氏陰性細菌，包括抗藥性菌株。此項批准旨在解決日益嚴重的抗生素抗藥性問題，這是全球面臨的重大健康威脅
- 2024 年 2 月，強生及其合作夥伴 Pharmacyclics LLC（艾伯維公司）獲得 FDA 批准，可擴大 IMBRUVICA（依魯替尼）口服混懸液的標籤。此擴展可治療已接受全身性治療的 CLL/SLL、WM 和 cGVHD 成年患者
- 2024年3月，強生宣布成功完成對Ambrx Biopharma, Inc.的收購。這家臨床階段生物製藥公司擁有專有的合成生物學技術平台，用於設計和開發下一代抗體藥物偶聯物（ADC）。此次收購為強生公司提供了一個獨特的機會來創造、開發和推廣標靶腫瘤療法
- 2024 年 2 月，AbbVie Inc. 和 Tentarix Biotherapeutics 宣佈建立合作關係，共同發現和開發腫瘤學和免疫學領域的條件活性、多特異性生物製劑。此次合作將利用 AbbVie 在這些領域的豐富經驗以及 Tentarix 專有的 Tentacles 平台
- 2021 年 9 月，賽諾菲與 Kadmon Holdings, Inc. 達成合併協議，後者是一家專注於開發和商業化針對大量未滿足醫療需求疾病的創新療法的生物製藥公司。此次收購符合賽諾菲通用藥物核心資產的成長策略，並將迅速將 Rezurock (belumosudil) 納入其移植產品組合
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
目录
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 MARKET END USER COVERAGE GRID
2.8 DBMR MARKET POSITION GRID
2.9 VENDOR SHARE ANALYSIS
2.1 SECONDARY SOURCES
2.11 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTAL ANALYSIS
4.2 PORTERS FIVE FORCES ANALYSIS
5 REGULATORY FRAMEWORK
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 INCREASING INCIDENCE OF HEMATOPOIETIC STEM CELL TRANSPLANTS (HSCT)
6.1.2 RISING AWARENESS CAMPAIGNS AND PATIENT EDUCATION
6.1.3 ADVANCEMENTS IN TREATMENT OPTIONS FOR GRAFT-VERSUS-HOST DISEASE (GVHD)
6.2 RESTRAINTS
6.2.1 HIGH COST OF MEDICATIONS AND SUPPORTIVE CARE
6.2.2 DISEASE HETEROGENEITY IN GRAFT-VERSUS-HOST DISEASE (GVHD) IMPLICATIONS FOR TREATMENT AND CLINICAL TRIALS
6.3 OPPORTUNITIES
6.3.1 MARKET EXPANSION THROUGH STRATEGIC INITIATIVES AND PARTNERSHIP
6.3.2 GROWING PIPELINE OF INNOVATIVE DRUGS FOR GVHD TREATMENT
6.3.3 EMPOWERING PATIENT-CENTRIC APPROACH TO GVHD TREATMENT
6.4 CHALLENGES
6.4.1 STRINGENT REGULATIONS IN GVHD THERAPIES
6.4.2 SAFETY CONCERN AND COMPLEXITIES DURING TREATMENT
7 GLOBAL GRAFT-VERSUS-HOST-DISEASE (GVHD) TREATMENT MARKET, BY TYPE
7.1 OVERVIEW
7.2 CHRONIC GVHD
7.2.1 CORTICOSTEROIDS
7.2.1.1 PREDNISOLONE
7.2.1.2 METHYLPREDNISOLONE
7.2.2 IMMUNOSUPPRESSIVE
7.2.2.1 MYCOPHENOLATE MOFETIL (MMF)
7.2.2.2 METHOTREXATE (MTX)
7.2.2.3 ANTITHYMOCYTE GLOBULIN (ATG)
7.2.2.4 OTHERS
7.2.3 CALCINEURIN INHIBITORS
7.2.4 OTHERS
7.2.5 BRANDED
7.2.5.1 REZUROCK
7.2.5.2 IMBRUVICA
7.2.5.3 JAKAFI
7.2.6 GENERIC
7.3 ACUTE GVHD
7.3.1 CORTICOSTEROIDS
7.3.1.1 METHYLPREDNISOLONE
7.3.1.2 PREDNISOLONE
7.3.2 IMMUNOSUPPRESSIVE
7.3.2.1 MYCOPHENOLATE MOFETIL (MMF)
7.3.2.2 RUXOLITINIB
7.3.2.3 OTHERS
7.3.3 CALCINEURIN INHIBITORS
7.3.3.1 TACROLIMUS (TAC)
7.3.3.2 CYCLOSPORIN (CSA)
7.3.4 OTHERS
7.4 PROPHYLACTIC
7.4.1 CYCLOSPORIN (CSA)
7.4.2 METHOTREXATE (MTX)
7.4.3 TACROLIMUS (TAC)
7.4.4 METHYLPREDNISOLONE
7.4.5 OTHERS
7.4.6 GENERIC
7.4.7 BRANDED
8 GLOBAL GRAFT-VERSUS-HOST- DISEASE (GVHD) TREATMENT MARKET, BY AGE
8.1 OVERVIEW
8.2 ADULTS
8.3 PEDIATRIC
9 GLOBAL GRAFT-VERSUS-HOST- DISEASE (GVHD) TREATMENT MARKET, BY GENDER
9.1 OVERVIEW
9.2 FEMALE
9.3 MALE
10 GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION
10.1 OVERVIEW
10.2 ORAL
10.3 INTRAVENOUS
10.4 TOPICAL
10.5 OTHERS
11 GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT
11.1 OVERVIEW
11.2 MEDICATION
11.2.1 CORTICOSTEROIDS
11.2.1.1 METHYLPREDNISOLONE
11.2.1.2 PREDNISOLONE
11.2.2 IMMUNOSUPPRESSIVE
11.2.2.1 MYCOPHENOLATE MOFETIL (MMF)
11.2.2.2 METHOTREXATE (MTX)
11.2.2.3 ANTITHYMOCYTE GLOBULIN (ATG)
11.2.2.4 OTHERS
11.2.3 CALCINEURIN INHIBITORS
11.2.3.1 TACROLIMUS (TAC)
11.2.3.2 CYCLOSPORIN (CSA)
11.2.3.3 OTHERS
11.2.4 BRANDED
11.2.4.1 REZUROCK
11.2.4.2 IMBRUVICA
11.2.4.3 JAKAFI
11.2.4.4 ORENCIA
11.2.4.5 OTHERS
11.2.5 GENERIC
11.3 THERAPY
12 GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER
12.1 OVERVIEW
12.2 HOSPITALS
12.2.1 PUBLIC
12.2.2 PRIVATE
12.3 TRANSPLANT CENTERS
12.4 INSTITUTES
12.5 SPECIALITY CENTERS
13 GLOBAL GRAFT-VERSUS-HOST-DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL
13.1 OVERVIEW
13.2 DIRECT TENDER
13.3 RETAIL SALES
13.3.1 HOSPITAL PHARMACY
13.3.2 RETAIL PHARMACY
13.3.3 ONLINE PHARMACY
13.4 OTHERS
14 GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY REGION
14.1 OVERVIEW
14.2 NORTH AMERICA
14.2.1 U.S.
14.2.2 CANADA
14.2.3 MEXICO
14.3 EUROPE
14.3.1 GERMANY
14.3.2 FRANCE
14.3.3 ITALY
14.3.4 U.K.
14.3.5 SPAIN
14.3.6 BELGIUM
14.3.7 RUSSIA
14.3.8 SWITZERLAND
14.3.9 DENMARK
14.3.10 REST OF EUROPE
14.4 ASIA-PACIFIC
14.4.1 JAPAN
14.4.2 CHINA
14.4.3 AUSTRALIA
14.4.4 SOUTH KOREA
14.4.5 INDIA
14.4.6 MALAYSIA
14.4.7 SINGAPORE
14.4.8 PHILIPPINES
14.4.9 INDONESIA
14.4.10 REST OF ASIA-PACIFIC
14.5 SOUTH AMERICA
14.5.1 BRAZIL
14.5.2 ARGENTINA
14.5.3 REST OF SOUTH AMERICA
14.6 MIDDLE EAST AND AFRICA
14.6.1 SOUTH AFRICA
14.6.2 SAUDI ARABIA
14.6.3 U.A.E.
14.6.4 KUWAIT
14.6.5 BAHRAIN
14.6.6 REST OF MIDDLE EAST AND AFRICA
15 GLOBAL GRAFT VERSUS HOST DISEASE (GVHD) TREATMENT MARKET: COMPANY LANDSCAPE
15.1 COMPANY SHARE ANALYSIS: GLOBAL
15.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
15.3 COMPANY SHARE ANALYSIS: EUROPE
15.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
16 SWOT ANALYSIS
17 COMPANY PROFILE
17.1 BRISTOL-MYERS SQUIBB COMPANY
17.1.1 COMPANY SNAPSHOT
17.1.2 REVENUE ANALYSIS
17.1.3 COMPANY SHARE ANALYSIS
17.1.4 PRODUCT PORTFOLIO
17.1.5 RECENT DEVELOPMENTS
17.2 ABBVIE INC.
17.2.1 COMPANY SNAPSHOT
17.2.2 REVENUE ANALYSIS
17.2.3 COMPANY SHARE ANALYSIS
17.2.4 PRODUCT PORTFOLIO
17.2.5 RECENT DEVELOPMENTS
17.3 JANSSEN GLOBAL SERVICES, LLC
17.3.1 COMPANY SNAPSHOT
17.3.2 REVENUE ANALYSIS
17.3.3 COMPANY SHARE ANALYSIS
17.3.4 PRODUCT PORTFOLIO
17.3.5 RECENT DEVELOPMENTS
17.4 SANOFI
17.4.1 COMPANY SNAPSHOT
17.4.2 REVENUE ANALYSIS
17.4.3 COMPANY SHARE ANALYSIS
17.4.4 PRODUCT PORTFOLIO
17.4.5 RECENT DEVELOPMENTS/NEWS
17.5 INCYTE
17.5.1 COMPANY SNAPSHOT
17.5.2 REVENUE ANALYSIS
17.5.3 COMPANY SHARE ANALYSIS
17.5.4 PRODUCT PORTFOLIO
17.5.5 RECENT DEVELOPMENTS
17.6 ALKEM LABORATORIES LTD.
17.6.1 COMPANY SNAPSHOT
17.6.2 REVENUE ANALYSIS
17.6.3 PRODUCT PORTFOLIO
17.6.4 RECENT DEVELOPMENT
17.7 ASTELLAS PHARMA INC.
17.7.1 COMPANY SNAPSHOT
17.7.2 REVENUE ANALYSIS
17.7.3 PRODUCT PORTFOLIO
17.7.4 RECENT DEVELOPMENT
17.8 MALLINCKRODT
17.8.1 COMPANY SNAPSHOT
17.8.2 REVENUE ANALYSIS
17.8.3 PRODUCT PORTFOLIO
17.8.4 RECENT DEVELOPMENTS/NEWS
17.9 NOVARTIS AG
17.9.1 COMPANY SNAPSHOT
17.9.2 REVENUE ANALYSIS
17.9.3 PRODUCT PORTFOLIO
17.9.4 RECENT DEVELOPMENTS
18 QUESTIONNAIRE
19 RELATED REPORTS
表格列表
TABLE 1 GLOBAL GRAFT-VERSUS-HOST- DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 2 GLOBAL CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 3 GLOBAL CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 4 GLOBAL CORTICOSTEROIDS IN GRAFT-VERSUS-HOST- DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 5 GLOBAL IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 6 GLOBAL CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 7 GLOBAL BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 8 GLOBAL ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 9 GLOBAL ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 10 GLOBAL CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 11 GLOBAL IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 12 GLOBAL CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 13 GLOBAL PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 14 GLOBAL PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 15 GLOBAL PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 16 GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2018-2032 (USD THOUSAND)
TABLE 17 GLOBAL ADULTS IN GRAFT-VERSUS-HOST- DISEASE (GVHD) TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 18 GLOBAL PEDIATRIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 19 GLOBAL GRAFT-VERSUS-HOST- DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 20 GLOBAL FEMALE IN GRAFT-VERSUS-HOST- DISEASE (GVHD) TREATMENT MARKET, BY REGION, 20218-2032 (USD THOUSAND)
TABLE 21 GLOBAL MALE IN GRAFT-VERSUS-HOST- DISEASE (GVHD) TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 22 GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 23 GLOBAL ORAL IN GRAFT-VERSUS-HOST- DISEASE (GVHD) TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 24 GLOBAL INTRAVENOUS IN GRAFT-VERSUS-HOST- DISEASE (GVHD) TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 25 GLOBAL TOPICAL IN GRAFT-VERSUS-HOST- DISEASE (GVHD) TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 26 GLOBAL OTHERS IN GRAFT-VERSUS-HOST- DISEASE (GVHD) TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 27 GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 28 GLOBAL MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 29 GLOBAL MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 30 GLOBAL CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 31 GLOBAL IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 32 GLOBAL CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 33 GLOBAL MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 34 GLOBAL BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 35 GLOBAL THERAPY IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 36 GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 37 GLOBAL HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 38 GLOBAL HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 39 GLOBAL TRANSPLANT CENTERS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 40 GLOBAL INSTITUTES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 41 GLOBAL SPECIALTY CENTERS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 42 GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 43 GLOBAL DIRECT TENDER IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 44 GLOBAL RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 45 GLOBAL RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 46 GLOBAL OTHERS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 47 GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 48 NORTH AMERICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY COUNTRY, 2018-2032 (USD THOUSAND)
TABLE 49 NORTH AMERICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 50 NORTH AMERICA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 51 NORTH AMERICA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 52 NORTH AMERICA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 53 NORTH AMERICA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 54 NORTH AMERICA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 55 NORTH AMERICA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 56 NORTH AMERICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 57 NORTH AMERICA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 58 NORTH AMERICA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 59 NORTH AMERICA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 60 NORTH AMERICA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 61 NORTH AMERICA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 62 NORTH AMERICA ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 63 NORTH AMERICA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 64 NORTH AMERICA IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 65 NORTH AMERICA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 66 NORTH AMERICA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 67 NORTH AMERICA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 68 NORTH AMERICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 69 NORTH AMERICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2018-2032 (USD THOUSAND)
TABLE 70 NORTH AMERICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 71 NORTH AMERICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 72 NORTH AMERICA HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 73 NORTH AMERICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 74 NORTH AMERICA RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 75 U.S. GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 76 U.S. MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 77 U.S. CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 78 U.S. IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 79 U.S. CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 80 U.S. MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 81 U.S. BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 82 U.S. GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 83 U.S. CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 84 U.S. CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 85 U.S. IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 86 U.S. CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 87 U.S. BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 88 U.S. ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 89 U.S. CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 90 U.S. IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 91 U.S. CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 92 U.S. PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 93 U.S. PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 94 U.S. BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 95 U.S. GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 96 U.S. GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2018-2032 (USD THOUSAND)
TABLE 97 U.S. GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 98 U.S. GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 99 U.S. HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 100 U.S. GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 101 U.S. RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 102 CANADA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 103 CANADA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 104 CANADA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 105 CANADA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 106 CANADA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 107 CANADA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 108 CANADA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 109 CANADA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 110 CANADA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 111 CANADA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 112 CANADA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 113 CANADA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 114 CANADA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 115 CANADA ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 116 CANADA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 117 CANADA IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 118 CANADA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 119 CANADA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 120 CANADA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 121 CANADA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 122 CANADA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 123 CANADA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2018-2032 (USD THOUSAND)
TABLE 124 CANADA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 125 CANADA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 126 CANADA HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 127 CANADA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 128 CANADA RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 129 MEXICO GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 130 MEXICO MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 131 MEXICO CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 132 MEXICO IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 133 MEXICO CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 134 MEXICO MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 135 MEXICO BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 136 MEXICO GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 137 MEXICO CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 138 MEXICO CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 139 MEXICO IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 140 MEXICO CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 141 MEXICO BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 142 MEXICO ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 143 MEXICO CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 144 MEXICO IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 145 MEXICO CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 146 MEXICO PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 147 MEXICO PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 148 MEXICO GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 149 MEXICO GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2018-2032 (USD THOUSAND)
TABLE 150 MEXICO GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 151 MEXICO GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 152 MEXICO HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 153 MEXICO GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 154 MEXICO RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 155 EUROPE GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY COUNTRY, 2018-2032 (USD THOUSAND)
TABLE 156 EUROPE GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 157 EUROPE MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 158 EUROPE CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 159 EUROPE IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 160 EUROPE CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 161 EUROPE MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 162 EUROPE BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 163 EUROPE GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 164 EUROPE CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 165 METHYLPREDNISOLONE
TABLE 166 EUROPE IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 167 EUROPE CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 168 EUROPE BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 169 EUROPE ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 170 EUROPE CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 171 EUROPE IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 172 EUROPE CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 173 EUROPE PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 174 EUROPE PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 175 EUROPE GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 176 EUROPE GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2018-2032 (USD THOUSAND)
TABLE 177 EUROPE GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 178 EUROPE GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 179 EUROPE HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 180 EUROPE GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 181 EUROPE RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 182 GERMANY GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 183 GERMANY MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 184 GERMANY CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 185 GERMANY IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 186 GERMANY CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 187 GERMANY MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 188 GERMANY BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 189 GERMANY GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 190 GERMANY CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 191 GERMANY CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 192 GERMANY IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 193 GERMANY CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 194 GERMANY BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 195 GERMANY ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 196 GERMANY CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 197 GERMANY IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 198 GERMANY CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 199 GERMANY PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 200 GERMANY PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 201 GERMANY GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 202 GERMANY GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2018-2032 (USD THOUSAND)
TABLE 203 GERMANY GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 204 GERMANY GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 205 GERMANY HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 206 GERMANY GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 207 GERMANY RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 208 FRANCE GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 209 FRANCE MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 210 FRANCE CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 211 FRANCE IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 212 FRANCE CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 213 FRANCE MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 214 FRANCE BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 215 FRANCE GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 216 FRANCE CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 217 FRANCE CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 218 FRANCE IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 219 FRANCE CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 220 FRANCE BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 221 FRANCE ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 222 FRANCE CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 223 FRANCE IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 224 FRANCE CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 225 FRANCE PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 226 FRANCE PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 227 FRANCE GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 228 FRANCE GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2018-2032 (USD THOUSAND)
TABLE 229 FRANCE GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 230 FRANCE GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 231 FRANCE HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 232 FRANCE GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 233 FRANCE RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 234 ITALY GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 235 ITALY MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 236 ITALY CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 237 ITALY IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 238 ITALY CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 239 ITALY MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 240 ITALY BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 241 ITALY GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 242 ITALY CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 243 ITALY CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 244 ITALY IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 245 ITALY CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 246 ITALY BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 247 ITALY ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 248 ITALY CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 249 ITALY IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 250 ITALY CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 251 ITALY PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 252 ITALY PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 253 ITALY GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 254 ITALY GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2018-2032 (USD THOUSAND)
TABLE 255 ITALY GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 256 ITALY GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 257 ITALY HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 258 ITALY GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 259 ITALY RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 260 U.K. GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 261 U.K. MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 262 U.K. CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 263 U.K. IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 264 U.K. CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 265 U.K. MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 266 U.K. BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 267 U.K. GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 268 U.K. CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 269 U.K. CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 270 U.K. IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 271 U.K. CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 272 U.K. BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 273 U.K. ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 274 U.K. CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 275 U.K. IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 276 U.K. CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 277 U.K. PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 278 U.K. PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 279 U.K. GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 280 U.K. GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2018-2032 (USD THOUSAND)
TABLE 281 U.K. GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 282 U.K. GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 283 U.K. HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 284 U.K. GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 285 U.K. RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 286 SPAIN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 287 SPAIN MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 288 SPAIN CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 289 SPAIN IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 290 SPAIN CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 291 SPAIN MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 292 SPAIN BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 293 SPAIN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 294 SPAIN CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 295 SPAIN CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 296 SPAIN IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 297 SPAIN CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 298 SPAIN BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 299 SPAIN ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 300 SPAIN CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 301 SPAIN IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 302 SPAIN CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 303 SPAIN PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 304 SPAIN PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 305 SPAIN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 306 SPAIN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2018-2032 (USD THOUSAND)
TABLE 307 SPAIN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 308 SPAIN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 309 SPAIN HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 310 SPAIN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 311 SPAIN RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 312 BELGIUM GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 313 BELGIUM MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 314 BELGIUM CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 315 BELGIUM IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 316 BELGIUM CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 317 BELGIUM MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 318 BELGIUM BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 319 BELGIUM GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 320 BELGIUM CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 321 BELGIUM CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 322 BELGIUM IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 323 BELGIUM CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 324 BELGIUM BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 325 BELGIUM ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 326 BELGIUM CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 327 BELGIUM IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 328 BELGIUM CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 329 BELGIUM PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 330 BELGIUM PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 331 BELGIUM GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 332 BELGIUM GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2018-2032 (USD THOUSAND)
TABLE 333 BELGIUM GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 334 BELGIUM GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 335 BELGIUM HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 336 BELGIUM GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 337 BELGIUM RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 338 RUSSIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 339 RUSSIA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 340 RUSSIA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 341 RUSSIA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 342 RUSSIA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 343 RUSSIA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 344 RUSSIA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 345 RUSSIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 346 RUSSIA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 347 RUSSIA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 348 RUSSIA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 349 RUSSIA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 350 RUSSIA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 351 RUSSIA ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 352 RUSSIA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 353 RUSSIA IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 354 RUSSIA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 355 RUSSIA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 356 RUSSIA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 357 RUSSIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 358 RUSSIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2018-2032 (USD THOUSAND)
TABLE 359 RUSSIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 360 RUSSIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 361 RUSSIA HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 362 RUSSIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 363 RUSSIA RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 364 SWITZERLAND GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 365 SWITZERLAND MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 366 SWITZERLAND CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 367 SWITZERLAND IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 368 SWITZERLAND CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 369 SWITZERLAND MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 370 SWITZERLAND BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 371 SWITZERLAND GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 372 SWITZERLAND CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 373 SWITZERLAND CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 374 SWITZERLAND IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 375 SWITZERLAND CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 376 SWITZERLAND BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 377 SWITZERLAND ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 378 SWITZERLAND CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 379 SWITZERLAND IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 380 SWITZERLAND CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 381 SWITZERLAND PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 382 SWITZERLAND PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 383 SWITZERLAND GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 384 SWITZERLAND GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2018-2032 (USD THOUSAND)
TABLE 385 SWITZERLAND GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 386 SWITZERLAND GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 387 SWITZERLAND HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 388 SWITZERLAND GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 389 SWITZERLAND RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 390 DENMARK GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 391 DENMARK MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 392 DENMARK CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 393 DENMARK IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 394 DENMARK CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 395 DENMARK MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 396 DENMARK BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 397 DENMARK GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 398 DENMARK CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 399 DENMARK CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 400 DENMARK IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 401 DENMARK CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 402 DENMARK BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 403 DENMARK ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 404 DENMARK CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 405 DENMARK IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 406 DENMARK CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 407 DENMARK PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 408 DENMARK PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 409 DENMARK GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 410 DENMARK GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2018-2032 (USD THOUSAND)
TABLE 411 DENMARK GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 412 DENMARK GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 413 DENMARK HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 414 DENMARK GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 415 DENMARK RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 416 REST OF EUROPE GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 417 ASIA-PACIFIC GRAFT VERSUS HOST DISEASE MARKET, BY COUNTRY, 2018-2032 (USD THOUSAND)
TABLE 418 ASIA-PACIFIC GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 419 ASIA-PACIFIC MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 420 ASIA-PACIFIC CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 421 ASIA-PACIFIC IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 422 ASIA-PACIFIC CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 423 ASIA-PACIFIC MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 424 ASIA-PACIFIC BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 425 ASIA-PACIFIC GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 426 ASIA-PACIFIC CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 427 ASIA-PACIFIC CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 428 ASIA-PACIFIC IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 429 ASIA-PACIFIC CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 430 ASIA-PACIFIC BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 431 ASIA-PACIFIC ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 432 ASIA-PACIFIC CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 433 ASIA-PACIFIC IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 434 ASIA-PACIFIC CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 435 ASIA-PACIFIC PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 436 ASIA-PACIFIC PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 437 ASIA-PACIFIC GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 438 ASIA-PACIFIC GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2018-2032 (USD THOUSAND)
TABLE 439 ASIA-PACIFIC GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 440 ASIA-PACIFIC GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 441 ASIA-PACIFIC HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 442 ASIA-PACIFIC GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 443 ASIA-PACIFIC RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 444 JAPAN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 445 JAPAN MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 446 JAPAN CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 447 JAPAN IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 448 JAPAN CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 449 JAPAN MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 450 JAPAN BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 451 JAPAN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 452 JAPAN CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 453 JAPAN CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 454 JAPAN IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 455 JAPAN CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 456 JAPAN BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 457 JAPAN ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 458 JAPAN CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 459 JAPAN IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 460 JAPAN CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 461 JAPAN PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 462 JAPAN PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 463 JAPAN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 464 JAPAN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2018-2032 (USD THOUSAND)
TABLE 465 JAPAN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 466 JAPAN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 467 JAPAN HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 468 JAPAN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 469 JAPAN RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 470 CHINA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 471 CHINA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 472 CHINA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 473 CHINA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 474 CHINA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 475 CHINA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 476 CHINA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 477 CHINA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 478 CHINA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 479 CHINA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 480 CHINA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 481 CHINA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 482 CHINA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 483 CHINA ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 484 CHINA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 485 CHINA IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 486 CHINA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 487 CHINA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 488 CHINA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 489 CHINA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 490 CHINA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2018-2032 (USD THOUSAND)
TABLE 491 CHINA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 492 CHINA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 493 CHINA HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 494 CHINA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 495 CHINA RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 496 AUSTRALIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 497 AUSTRALIA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 498 AUSTRALIA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 499 AUSTRALIA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 500 AUSTRALIA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 501 AUSTRALIA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 502 AUSTRALIA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 503 AUSTRALIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 504 AUSTRALIA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 505 AUSTRALIA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 506 AUSTRALIA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 507 AUSTRALIA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 508 AUSTRALIA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 509 AUSTRALIA ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 510 AUSTRALIA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 511 AUSTRALIA IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 512 AUSTRALIA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 513 AUSTRALIA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 514 AUSTRALIA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 515 AUSTRALIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 516 AUSTRALIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2018-2032 (USD THOUSAND)
TABLE 517 AUSTRALIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 518 AUSTRALIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 519 AUSTRALIA HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 520 AUSTRALIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 521 AUSTRALIA RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 522 SOUTH KOREA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 523 SOUTH KOREA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 524 SOUTH KOREA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 525 SOUTH KOREA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 526 SOUTH KOREA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 527 SOUTH KOREA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 528 SOUTH KOREA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 529 SOUTH KOREA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 530 SOUTH KOREA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 531 SOUTH KOREA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 532 SOUTH KOREA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 533 SOUTH KOREA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 534 SOUTH KOREA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 535 SOUTH KOREA ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 536 SOUTH KOREA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 537 SOUTH KOREA IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 538 SOUTH KOREA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 539 SOUTH KOREA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 540 SOUTH KOREA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 541 SOUTH KOREA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 542 SOUTH KOREA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2018-2032 (USD THOUSAND)
TABLE 543 SOUTH KOREA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 544 SOUTH KOREA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 545 SOUTH KOREA HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 546 SOUTH KOREA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 547 SOUTH KOREA RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 548 INDIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 549 INDIA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 550 INDIA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 551 INDIA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 552 INDIA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 553 INDIA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 554 INDIA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 555 INDIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 556 INDIA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 557 INDIA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 558 INDIA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 559 INDIA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 560 INDIA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 561 INDIA ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 562 INDIA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 563 INDIA IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 564 INDIA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 565 INDIA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 566 INDIA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 567 INDIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 568 INDIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2018-2032 (USD THOUSAND)
TABLE 569 INDIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 570 INDIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 571 INDIA HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 572 INDIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 573 INDIA RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 574 MALAYSIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 575 MALAYSIA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 576 MALAYSIA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 577 MALAYSIA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 578 MALAYSIA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 579 MALAYSIA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 580 MALAYSIA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 581 MALAYSIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 582 MALAYSIA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 583 MALAYSIA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 584 MALAYSIA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 585 MALAYSIA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 586 MALAYSIA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 587 MALAYSIA ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 588 MALAYSIA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 589 MALAYSIA IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 590 MALAYSIA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 591 MALAYSIA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 592 MALAYSIA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 593 MALAYSIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 594 MALAYSIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2018-2032 (USD THOUSAND)
TABLE 595 MALAYSIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 596 MALAYSIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 597 MALAYSIA HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 598 MALAYSIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 599 MALAYSIA RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 600 SINGAPORE GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 601 SINGAPORE MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 602 SINGAPORE CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 603 SINGAPORE IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 604 SINGAPORE CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 605 SINGAPORE MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 606 SINGAPORE BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 607 SINGAPORE GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 608 SINGAPORE CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 609 SINGAPORE CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 610 SINGAPORE IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 611 SINGAPORE CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 612 SINGAPORE BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 613 SINGAPORE ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 614 SINGAPORE CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 615 SINGAPORE IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 616 SINGAPORE CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 617 SINGAPORE PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 618 SINGAPORE PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 619 SINGAPORE GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 620 SINGAPORE GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2018-2032 (USD THOUSAND)
TABLE 621 SINGAPORE GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 622 SINGAPORE GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 623 SINGAPORE HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 624 SINGAPORE GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 625 SINGAPORE RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 626 PHILIPPINES GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 627 PHILIPPINES MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 628 PHILIPPINES CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 629 PHILIPPINES IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 630 PHILIPPINES CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 631 PHILIPPINES MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 632 PHILIPPINES BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 633 PHILIPPINES GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 634 PHILIPPINES CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 635 PHILIPPINES CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 636 PHILIPPINES IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 637 PHILIPPINES CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 638 PHILIPPINES BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 639 PHILIPPINES ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 640 PHILIPPINES CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 641 PHILIPPINES IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 642 PHILIPPINES CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 643 PHILIPPINES PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 644 PHILIPPINES PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 645 PHILIPPINES GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 646 PHILIPPINES GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2018-2032 (USD THOUSAND)
TABLE 647 PHILIPPINES GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 648 PHILIPPINES GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 649 PHILIPPINES HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 650 PHILIPPINES GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 651 PHILIPPINES RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 652 INDONESIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 653 INDONESIA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 654 INDONESIA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 655 INDONESIA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 656 INDONESIA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 657 INDONESIA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 658 INDONESIA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 659 INDONESIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 660 INDONESIA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 661 INDONESIA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 662 INDONESIA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 663 INDONESIA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 664 INDONESIA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 665 INDONESIA ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 666 INDONESIA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 667 INDONESIA IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 668 INDONESIA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 669 INDONESIA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 670 INDONESIA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 671 INDONESIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 672 INDONESIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2018-2032 (USD THOUSAND)
TABLE 673 INDONESIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 674 INDONESIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 675 INDONESIA HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 676 INDONESIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 677 INDONESIA RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 678 REST OF ASIA-PACIFIC GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 679 SOUTH AMERICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY COUNTRY, 2018-2032 (USD THOUSAND)
TABLE 680 SOUTH AMERICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 681 SOUTH AMERICA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 682 SOUTH AMERICA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 683 SOUTH AMERICA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 684 SOUTH AMERICA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 685 SOUTH AMERICA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 686 SOUTH AMERICA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 687 SOUTH AMERICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 688 SOUTH AMERICA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 689 SOUTH AMERICA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 690 SOUTH AMERICA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 691 SOUTH AMERICA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 692 SOUTH AMERICA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 693 SOUTH AMERICA ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 694 SOUTH AMERICA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 695 SOUTH AMERICA IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 696 SOUTH AMERICA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 697 SOUTH AMERICA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 698 SOUTH AMERICA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 699 SOUTH AMERICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 700 SOUTH AMERICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2018-2032 (USD THOUSAND)
TABLE 701 SOUTH AMERICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 702 SOUTH AMERICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 703 SOUTH AMERICA HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 704 SOUTH AMERICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 705 SOUTH AMERICA RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 706 BRAZIL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 707 BRAZIL MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 708 BRAZIL CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 709 BRAZIL IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 710 BRAZIL CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 711 BRAZIL MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 712 BRAZIL BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 713 BRAZIL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 714 BRAZIL CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 715 BRAZIL CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 716 BRAZIL IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 717 BRAZIL CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 718 BRAZIL BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 719 BRAZIL ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 720 BRAZIL CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 721 BRAZIL IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 722 BRAZIL CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 723 BRAZIL PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 724 BRAZIL PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 725 BRAZIL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 726 BRAZIL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2018-2032 (USD THOUSAND)
TABLE 727 BRAZIL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 728 BRAZIL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 729 BRAZIL HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 730 BRAZIL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 731 BRAZIL RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 732 ARGENTINA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 733 ARGENTINA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 734 ARGENTINA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 735 ARGENTINA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 736 ARGENTINA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 737 ARGENTINA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 738 ARGENTINA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 739 ARGENTINA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 740 ARGENTINA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 741 ARGENTINA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 742 ARGENTINA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 743 ARGENTINA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 744 ARGENTINA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 745 ARGENTINA ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 746 ARGENTINA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 747 ARGENTINA IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 748 ARGENTINA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 749 ARGENTINA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 750 ARGENTINA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 751 ARGENTINA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 752 ARGENTINA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2018-2032 (USD THOUSAND)
TABLE 753 ARGENTINA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 754 ARGENTINA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 755 ARGENTINA HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 756 ARGENTINA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 757 ARGENTINA RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 758 REST OF SOUTH AMERICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 759 MIDDLE EAST AND AFRICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY COUNTRY, 2018-2032 (USD THOUSAND)
TABLE 760 MIDDLE EAST AND AFRICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 761 MIDDLE EAST AND AFRICA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 762 MIDDLE EAST AND AFRICA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 763 MIDDLE EAST AND AFRICA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 764 MIDDLE EAST AND AFRICA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 765 MIDDLE EAST AND AFRICA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 766 MIDDLE EAST AND AFRICA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 767 MIDDLE EAST AND AFRICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 768 MIDDLE EAST AND AFRICA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 769 MIDDLE EAST AND AFRICA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 770 MIDDLE EAST AND AFRICA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 771 MIDDLE EAST AND AFRICA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 772 MIDDLE EAST AND AFRICA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 773 MIDDLE EAST AND AFRICA ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 774 MIDDLE EAST AND AFRICA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 775 MIDDLE EAST AND AFRICA IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 776 MIDDLE EAST AND AFRICA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 777 MIDDLE EAST AND AFRICA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 778 MIDDLE EAST AND AFRICA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 779 MIDDLE EAST AND AFRICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 780 MIDDLE EAST AND AFRICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2018-2032 (USD THOUSAND)
TABLE 781 MIDDLE EAST AND AFRICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 782 MIDDLE EAST AND AFRICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 783 MIDDLE EAST AND AFRICA HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 784 MIDDLE EAST AND AFRICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 785 MIDDLE EAST AND AFRICA RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 786 SOUTH AFRICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 787 SOUTH AFRICA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 788 SOUTH AFRICA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 789 SOUTH AFRICA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 790 SOUTH AFRICA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 791 SOUTH AFRICA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 792 SOUTH AFRICA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 793 SOUTH AFRICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 794 SOUTH AFRICA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 795 SOUTH AFRICA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 796 SOUTH AFRICA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 797 SOUTH AFRICA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 798 SOUTH AFRICA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 799 SOUTH AFRICA ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 800 SOUTH AFRICA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 801 SOUTH AFRICA IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 802 SOUTH AFRICA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 803 SOUTH AFRICA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 804 SOUTH AFRICA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 805 SOUTH AFRICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 806 SOUTH AFRICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2018-2032 (USD THOUSAND)
TABLE 807 SOUTH AFRICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 808 SOUTH AFRICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 809 SOUTH AFRICA HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 810 SOUTH AFRICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 811 SOUTH AFRICA RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 812 SAUDI ARABIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 813 SAUDI ARABIA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 814 SAUDI ARABIA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 815 SAUDI ARABIA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 816 SAUDI ARABIA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 817 SAUDI ARABIA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 818 SAUDI ARABIA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 819 SAUDI ARABIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 820 SAUDI ARABIA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 821 SAUDI ARABIA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 822 SAUDI ARABIA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 823 SAUDI ARABIA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 824 SAUDI ARABIA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 825 SAUDI ARABIA ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 826 SAUDI ARABIA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 827 SAUDI ARABIA IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 828 SAUDI ARABIA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 829 SAUDI ARABIA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 830 SAUDI ARABIA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 831 SAUDI ARABIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 832 SAUDI ARABIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2018-2032 (USD THOUSAND)
TABLE 833 SAUDI ARABIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 834 SAUDI ARABIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 835 SAUDI ARABIA HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 836 SAUDI ARABIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 837 SAUDI ARABIA RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 838 U.A.E. GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 839 U.A.E. MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 840 U.A.E. CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 841 U.A.E. IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 842 U.A.E. CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 843 U.A.E. MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 844 U.A.E. BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 845 U.A.E. GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 846 U.A.E. CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 847 U.A.E. CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 848 U.A.E. IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 849 U.A.E. CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 850 U.A.E. BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 851 U.A.E. ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 852 U.A.E. CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 853 U.A.E. IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 854 U.A.E. CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 855 U.A.E. PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 856 U.A.E. PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 857 U.A.E. GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 858 U.A.E. GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2018-2032 (USD THOUSAND)
TABLE 859 U.A.E. GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 860 U.A.E. GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 861 U.A.E. HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 862 U.A.E. GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 863 U.A.E. RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 864 KUWAIT GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 865 KUWAIT MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 866 KUWAIT CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 867 KUWAIT IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 868 KUWAIT CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 869 KUWAIT MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 870 KUWAIT BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 871 KUWAIT GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 872 KUWAIT CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 873 KUWAIT CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 874 KUWAIT IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 875 KUWAIT CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 876 KUWAIT BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 877 KUWAIT ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 878 KUWAIT CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 879 KUWAIT IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 880 KUWAIT CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 881 KUWAIT PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 882 KUWAIT PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 883 KUWAIT GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 884 KUWAIT GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2018-2032 (USD THOUSAND)
TABLE 885 KUWAIT GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 886 KUWAIT GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 887 KUWAIT HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 888 KUWAIT GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 889 KUWAIT RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 890 BAHRAIN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 891 BAHRAIN MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 892 BAHRAIN CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 893 BAHRAIN IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 894 BAHRAIN CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 895 BAHRAIN MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 896 BAHRAIN BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 897 BAHRAIN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 898 BAHRAIN CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 899 BAHRAIN CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 900 BAHRAIN IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 901 BAHRAIN CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 902 BAHRAIN BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 903 BAHRAIN ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 904 BAHRAIN CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 905 BAHRAIN IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 906 BAHRAIN CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 907 BAHRAIN PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 908 BAHRAIN PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 909 BAHRAIN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 910 BAHRAIN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2018-2032 (USD THOUSAND)
TABLE 911 BAHRAIN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 912 BAHRAIN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 913 BAHRAIN HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 914 BAHRAIN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 915 BAHRAIN RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 916 REST OF MIDDLE EAST AND AFRICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
图片列表
FIGURE 1 GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET: SEGMENTATION
FIGURE 2 GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET: DATA TRIANGULATION
FIGURE 3 GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET: DROC ANALYSIS
FIGURE 4 GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS
FIGURE 5 GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET: MARKET END USER COVERAGE GRID
FIGURE 8 GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET: DBMR MARKET POSITION GRID
FIGURE 9 GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET: SEGMENTATION
FIGURE 11 THE GROWING NUMBER OF STEM CELL TRANSPLANTATIONS IS DRIVING THE GROWTH OF THE GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET FROM 2025 TO 2032
FIGURE 12 THE TREATMENT SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET IN 2025 AND 2032
FIGURE 13 NORTH AMERICA IS EXPECTED TO DOMINATE THE GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET AND IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2025 TO 2032
FIGURE 14 NORTH AMERICA IS THE FASTEST-GROWING REGION FOR GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET IN THE FORECAST PERIOD OF 2025 TO 2032
FIGURE 15 GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET: EXECUTIVE SUMMARY
FIGURE 16 STRATEGIC DECISIONS
FIGURE 17 TWO SEGMENTS COMPRISE THE GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT
FIGURE 18 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET
FIGURE 19 GLOBAL GRAFT-VERSUS-HOST-DISEASE (GVHD) TREATMENT MARKET: BY TYPE, 2024
FIGURE 20 GLOBAL GRAFT-VERSUS-HOST-DISEASE (GVHD) TREATMENT MARKET: BY TYPE, 2025-2032 (USD THOUSAND)
FIGURE 21 GLOBAL GRAFT-VERSUS-HOST-DISEASE (GVHD) TREATMENT MARKET: BY TYPE, CAGR (2025-2032)
FIGURE 22 GLOBAL GRAFT-VERSUS-HOST-DISEASE (GVHD) TREATMENT MARKET: BY TYPE, LIFELINE CURVE
FIGURE 23 GLOBAL GRAFT-VERSUS-HOST- DISEASE (GVHD) TREATMENT MARKET: BY AGE, 2024
FIGURE 24 GLOBAL GRAFT-VERSUS-HOST- DISEASE (GVHD) TREATMENT MARKET: BY AGE, 2025-2032 (USD THOUSAND)
FIGURE 25 GLOBAL GRAFT-VERSUS-HOST- DISEASE (GVHD) TREATMENT MARKET: BY AGE, CAGR (2025-2032)
FIGURE 26 GLOBAL GRAFT-VERSUS-HOST- DISEASE (GVHD) TREATMENT MARKET: BY AGE, LIFELINE CURVE
FIGURE 27 GLOBAL GRAFT-VERSUS-HOST- DISEASE (GVHD) TREATMENT MARKET: BY GENDER, 2024
FIGURE 28 GLOBAL GRAFT-VERSUS-HOST- DISEASE (GVHD) TREATMENT MARKET: BY GENDER, 2025-2032 (USD THOUSAND)
FIGURE 29 GLOBAL GRAFT-VERSUS-HOST- DISEASE (GVHD) TREATMENT MARKET: BY GENDER, CAGR (2025-2032)
FIGURE 30 GLOBAL GRAFT-VERSUS-HOST- DISEASE (GVHD) TREATMENT MARKET: BY GENDER, LIFELINE CURVE
FIGURE 31 GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET: BY METHOD OF ADMINISTRATION, 2024
FIGURE 32 GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET: BY METHOD OF ADMINISTRATION, 2025-2032 (USD THOUSAND)
FIGURE 33 GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET: BY METHOD OF ADMINISTRATION, CAGR (2025-2032)
FIGURE 34 GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET: BY METHOD OF ADMINISTRATION, LIFELINE CURVE
FIGURE 35 GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET: BY TREATMENT, 2024
FIGURE 36 GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET: BY TREATMENT, 2025-2032 (USD THOUSAND)
FIGURE 37 GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET: BY TREATMENT, CAGR (2025-2032)
FIGURE 38 GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET: BY TREATMENT, LIFELINE CURVE
FIGURE 39 GLOBAL GRAFT-VERSUS-HOST-DISEASE (GVHD) TREATMENT MARKET: BY END USER 2024
FIGURE 40 GLOBAL GRAFT-VERSUS-HOST-DISEASE (GVHD) TREATMENT MARKET: BY END USER, 2025-2032 (USD THOUSAND)
FIGURE 41 GLOBAL GRAFT-VERSUS-HOST-DISEASE (GVHD) TREATMENT MARKET: END USER, CAGR (2025-2032)
FIGURE 42 GLOBAL GRAFT-VERSUS-HOST-DISEASE (GVHD) TREATMENT MARKET: END USER, LIFELINE CURVE
FIGURE 43 GLOBAL GRAFT-VERSUS-HOST-DISEASE (GVHD) TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2024
FIGURE 44 GLOBAL GRAFT-VERSUS-HOST-DISEASE (GVHD) TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2025-2032 (USD THOUSAND)
FIGURE 45 GLOBAL GRAFT-VERSUS-HOST-DISEASE (GVHD) TREATMENT MARKET: DISTRIBUTION CHANNEL, CAGR (2025-2032)
FIGURE 46 GLOBAL GRAFT-VERSUS-HOST-DISEASE (GVHD) TREATMENT MARKET: DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 47 GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET: SNAPSHOT (2024)
FIGURE 48 GLOBAL GRAFT VERSUS HOST DISEASE (GVHD) TREATMENT MARKET: COMPANY SHARE 2024 (%)
FIGURE 49 NORTH AMERICA GRAFT VERSUS HOST DISEASE (GVHD) TREATMENT MARKET: COMPANY SHARE 2024 (%)
FIGURE 50 EUROPE GRAFT VERSUS HOST DISEASE (GVHD) TREATMENT MARKET: COMPANY SHARE 2024 (%)
FIGURE 51 AISA-PACIFIC GRAFT VERSUS HOST DISEASE (GVHD) TREATMENT MARKET: COMPANY SHARE 2024 (%)
研究方法
数据收集和基准年分析是使用具有大样本量的数据收集模块完成的。该阶段包括通过各种来源和策略获取市场信息或相关数据。它包括提前检查和规划从过去获得的所有数据。它同样包括检查不同信息源中出现的信息不一致。使用市场统计和连贯模型分析和估计市场数据。此外，市场份额分析和关键趋势分析是市场报告中的主要成功因素。要了解更多信息，请请求分析师致电或下拉您的询问。
DBMR 研究团队使用的关键研究方法是数据三角测量，其中包括数据挖掘、数据变量对市场影响的分析和主要（行业专家）验证。数据模型包括供应商定位网格、市场时间线分析、市场概览和指南、公司定位网格、专利分析、定价分析、公司市场份额分析、测量标准、全球与区域和供应商份额分析。要了解有关研究方法的更多信息，请向我们的行业专家咨询。
可定制
Data Bridge Market Research 是高级形成性研究领域的领导者。我们为向现有和新客户提供符合其目标的数据和分析而感到自豪。报告可定制，包括目标品牌的价格趋势分析、了解其他国家的市场（索取国家列表）、临床试验结果数据、文献综述、翻新市场和产品基础分析。目标竞争对手的市场分析可以从基于技术的分析到市场组合策略进行分析。我们可以按照您所需的格式和数据样式添加您需要的任意数量的竞争对手数据。我们的分析师团队还可以为您提供原始 Excel 文件数据透视表（事实手册）中的数据，或者可以帮助您根据报告中的数据集创建演示文稿。
